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Background: Human telomerase has an essential RNA component and is an 
ideal target for developing rules correlating oligonucleotide chemistry wi h 
disruption of biological function. Similarly, peptide nucleic acids (PNAs), DNA 
analogs that bind complementary sequences with high affinity, are outstanding 
candidates for inducing phenotypic changes through hybridization. 
Results: We identify PNAs directed to nontemplate regions of the telomerase 
RNA that can overcome RNA secondary structure and inhibit telomerase by 
intercepting the RNA component prior to holoenzyme assembly. Relative 
potencies of inhibition delineate putative structural domains. We describe a 
novel protocol for introducing PNAs into eukaryotie cells and report efficient 
inhibition of cellular telomerase by PNAs. 
Conclusions: PNAs directed to nontemplate regions are a new class of 
telomerase inhibitor and may contribute to the development of novel 
antiproliferative agents. The dependence of inhibition by nontemplate-directed 
PNAs on target sequence suggests that PNAs have great potential for mapping 
nucleic acid structure and predictably regulating biological processes. Our 
simple method for introducing PNAs into cells will not only be useful for probing 
the complex biology surrounding telomere length maintenance but can be 
broadly applied for controlling gene expression and functional genomics. 
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I n t roduct ion  
Progress in genome sequencing and the use of gene 
expression arrays as a high-throughput method for exam- 
ining mRNA levels are expanding our knowledge of the 
sequence and expression of cellular proteins faster than 
our understanding of their function. Oligonucleotides, 
with their inherent potential for specific recognition, can 
be used to deconvolute the complex role of proteins 
within cells and sort the diverse interactions of individual 
proteins. To create 'knock out' phenotypes that can be 
interpreted, however, oligonucleotides must be delivered 
across the cell membrane and then bind complementary 
sequences with high specificity. 
Peptide nucleic acids (PNAs), DNA analogs that have N- 
(2-aminoethyl) glycine linkages rather than a phosphodi- 
ester backbone [1], possess properties that make them 
leading candidates for this task, including a propensity for 
rapid [2] and high-affinity binding [1,3], resistance to 
degradation by nucleases and proteases [4], poor affinity 
for proteins that normally bind nucleic acids [5], and high 
mismatch discrimination [3]. To take full advantage of 
these favorable properties it is necessary to develop rules 
to predict the propensity for hybridization of PNAs to 
varied nucleic acid sequences and structures. Such rules 
have already been developed in vitro, where hybridization 
at polypurine-polypyrimidine sequences [6,7], inverted 
repeats [8,9], AT-rich regions [9] and trinucleotide repeats 
[10] appear to be most favored. A similar understanding, 
however, has yet to be developed for hybridization within 
cells, an environment characterized by an enormous com- 
plexity of nucleic acid sequence, chemistry and structure. 
Human telomerase [11], a ribonucleoprotein that is 
responsible for maintaining the length of telomeres, is an 
excellent model for developing rules correlating oligomer 
chemistry, target sequence and target structure. The RNA 
component of telomerase (hTR)[12] contains an l 1-base 
region (nucleotides +46 to +56) that acts as a template for 
binding and extending telomeres. This critical role 
requires that this region of hTR be single stranded, 
making it one of the most accessible of all cellular nucleic 
acid sequences and an ideal target for oligomer hybridiza- 
tion. Less is known about the remaining 440 bases of 
hTR, but deletion analysis has shown that much of this 
sequence is not required for activity ([13,14]; 
V.M. Tesmer, S.E. Holt, B.C. Frank, X. Yi, D. Aisner, 
M.M. Ouellette, J.W. Shay and W.E. Wright, personal 
communication). In vitro experiments demonstrate that a 
catalytic-core gion of nucleotides +44 to +325 retains 5% 
wild-type activity, whereas the region from bases +33 to 
+325 retains full activity (V.M. Tesmer, et al., and 
W.E. Wright, personal communication). Telomerase can 
be reconstituted in vitro upon expression of the genes for 
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A scheme for reconstitution of telomerase 
holoenzyme from hTR and hTERT. PNAs can 
inhibit telomerase activity by binding to 
unfolded RNA, to folded RNA or to RNA bound 
by protein in the holoenzyme. The structure of 
hTR is unknown but it is reasonable to expect 
that some base-paired structure is formed prior 
to holoenzyme assembly. 
hTR and its protein component, hTERT [14,15], allowing 
a comparison between oligonucleotide-mediated inhibi- 
tion at three different stages--the unfolded RNA, the 
folded RNA and the holoenzyme. 
There is also great practical interest in developing effec- 
tive telomerase inhibitors because telomerase activity has 
been found in many types of human tumors, but not in 
most types of somatic cells [16,17]. This has led to the 
hypothesis that activation of telomerase is necessary for 
sustained proliferation of most tumor cells and that telom- 
erase inhibitors might represent a novel class of antiprolif- 
erative agents [18,19]. This hypothesis has been 
vigorously debated; potent oligonucleotide inhibitors of 
telomerase could be used to validate the connection 
between telomerase and cancer because of the stringent 
control inherent in oligonucleotide hybridization--the 
match oligomer should have a physiological effect, 
whereas a mismatch-containing oligomer should not. A 
phosphorothioate oligomer has recently been approved as 
a drug to treat CMV retinitis and several other oligonu- 
cleotide drugs are in clinical trials [20], suggesting that 
oligonucleotide-based inhibitors of human telomerase 
would be lead compounds for the development of 
chemotherapeutic agents. 
We have shown previously that PNAs complementary to 
the l 1-base template of hTR are potent inhibitors of 
human telomerase when tested in vitro [21,22]. We now 
describe two advances that expand the options for dis- 
rupting cellular function using PNAs. We report that 
PNAs directed to regions of hTR other than the 11-base 
template are a new class of inhibitor that act by intercept- 
ing the RNA component prior to assembly with the 
protein component. As with any class of drugs, it is likely 
that inhibitor resistance will arise upon prolonged treat- 
ment, and the availability of multiple types of telomerase 
inhibitors, each possessing a separate binding site, is 
likely to facilitate effective long-term therapy. We then 
report the discovery that PNAs can be delivered into 
eukaryotic ells using a simple protocol and use this pro- 
tocol to demonstrate hat PNAs can sequence-selectively 
block cellular telomerase activity. The observation that 
PNAs can be delivered into cells by adapting a widely 
used technology and that they can then inhibit a cellular 
RNA target has implications that extend beyond telom- 
erase inhibition to the development of a chemical-based 
technology for conditional repression of gene expression. 
Results and discussion 
Effect of target sequence and structure on inhibition of 
telomerase 
The RNA component (hTR) and protein component 
(hTERT) of human telomerase can be expressed in vitro 
using run-off transcription and rabbit reticulocyte lysate, 
respectively, and then mixed to generate active telom- 
erase [15]. The ability to reconstitute telomerase from its 
components permits the individual stages of ribonucleo- 
protein assembly to be isolated and their susceptibility to 
PNA binding to be examined and compared. PNAs can 
bind to hTR as it folds, to hTR that has been permitted to 
fold in the absence of protein or to the holoenzyme after 
RNA and protein have associated (Figure 1). Relative 
levels of inhibition would probably reflect differences in 
structure and stability of RNA target sites, information 
that will contribute to a model for the telomerase RNA 
and advance design of improved antitelomerase agents. 
We initiated our studies by correlating ribonucleoprotein 
assembly with the efficacy of inhibition by PNAs 3, 4 and 
7 (Table 1, Figure 2). These three PNAs were chosen to 
be complementary to target sequences likely to possess 
differing degrees of secondary structure and functional 
importance. PNA 3 is complementary to the 11-base RNA 
template region, which is both critical for telomerase activ- 
ity and highly accessible to nucleic acid hybridization 
because of its role in telornere recognition and elongation. 
PNA4 is complementary to a sequence adjacent o the 
template that is likely to be less accessible than the tem- 
plate region itself. PNA7 is directed to a sequence 
49 bases distant from the template within a region of 
unknown structure but critical for catalysis ([13]; 
V.M. Tesmer, et al., and W.E. Wright, personal communi- 
cation). PNAs were added either to the isolated RNA 
component after it had been denatured and allowed to 
refold or to the telomerase holoenzyme after assembly of 
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Table 1 
Potency of inhibition of telomerase by PNAs as a function of template target and holoenzyme assembly. 
PNA/sequence/target site 
IC5o (~tM) 
Pre-assembly Post-assembly 
hTR (1-451) 5' 
1. CCTCCGCAACCC (1-12) 
2. GTTAGACAAAAAA (38-50) - -~  
3. CAGTTAGGGTTAG (46-58) 
4. CGCCCTTCTCA (57-67) 
5. CGGCGCCTACGCC (64-76) 
6. AGAAAAACAGCGC (93-105) 
7. TGAAAGTCAGCGA (105-117) 
8. TGCTCTAGAATGAAC (153-167) 
9. GCAGCTGACAT (176-186) 
i0. ACGGGCCAGCAGCTG (180-194) 
ii. CTTCGCGGTGGCA (291-303) 
12. GAGCCGAGTCCTG (430-442) 
13. TTGCTAGCCATC (not complementary to hTR) 
46-56 (hTR template region) 
I 
I 
I 
3' 
0.3 >100 
0.1 0.5 
0.02 0.03 
0.1 2.0 
1 >100 
0.1 >100 
0.1 >100 
15 >100 
0.1 >100 
0.01 10 
0.05 >100 
2 >100 
30 >100 
PNAs are listed amino to carboxyl termini and contain amino-terminal g ycine and carboxy-terminal lysine residues. 
the RNA and protein components. Telomerase activity 
was monitored using the polymerase chain reaction 
(PCR)-based telomere repeat amplification protocol 
(TRAP) [23]. 
The ICs0 values for inhibition of telomerase activity by 
PNA 3 (20-30 nM) were similar regardless of whether the 
PNA was added to the holoenzyme or to the isolated 
RNA component (Table 1). Inhibition of the holoenzyme 
appears to reflect the high accessibility of the template 
region that is needed to bind and extend telomeric DNA 
during normal functioning of the ribonucleoenzyme. By
contrast, inhibition by nontemplate-directed PNAs 4 and 
7 was acutely dependent on the state of ribonucleopro- 
tein assembly. When 4 was added to the RNA compo- 
nent prior to holoenzyme assembly, inhibition was 
characterized by a relatively low IC50 value of 100 nM. 
Addition of 4 to the holoenzyme, however, yielded a 
20-fold higher IC50 value of 2 ~tM. The difference in IC50 
values for inhibition by 7 was even more striking. Inhibi- 
tion of telomerase activity after addition to the isolated 
RNA was 100 nM, whereas no inhibition was detected 
upon addition of 7 to holoenzyme. 
Inhibition of telomerase upon addition of nontemplate- 
directed PNAs 4 and 7 to hTR encouraged us to test 
PNAs 1, 2, 5, 6 and 8--12 (Table 1) to determine whether 
inhibition was a general phenomenon and to probe the 
accessibility and importance of RNA structure throughout 
hTR. None of these PNAs was capable of inhibiting 
telomerase upon addition to holoenzyme, with the excep- 
tion of 2, which partially overlapped the template region, 
and 10, which inhibited with a modest IC50 value of 
10 ~tM. Every PNA, however, inhibited telomerase when 
added to hTR prior to ribonucleoprotein assembly, 
although the potency of inhibition varied 1000-fold 
depending on the target sequence. Inhibition by PNAs 1, 
2, 6, 7 and 9-11 was most potent, with IC50 values of 
10-300 nM. Inhibition by PNAs 5 and 12 was less potent, 
with IC50 values of 1-2 IxM, whereas inhibition by PNA 8 
was characterized by an ICs0 value of 15 laM, barely lower 
than a PNA that is not complementary to hTR (PNA 13). 
PNA-mediated inhibition as a probe for hTR structure and 
hTR/hTERT assembly 
Several conclusions can be drawn from the inhibition of 
telomerase by nontemplate-directed PNAs. PNA-medi- 
ated inhibition is not restricted to PNAs targeted to the 
intrinsically accessible RNA template, as demonstrated by 
our observation of IC50 values as low as 10-100 riM. 
Potent inhibition was surprising because we had not previ- 
ously observed significant levels of inhibition by nontem- 
plate-directed PNAs when using telomerase obtained 
from extracts of cultured cells, and because there is no 
obvious reason why nontemplate RNA should be accessi- 
ble to hybridization with an incoming oligomer. We 
observe inhibition in these studies because the ability to 
reconstitute telomerase in vitro allows us to test separately 
the effect of inhibitor binding to hTR alone, a property 
that should be generally valuable during screening for 
other classes of telomerase inhibitor. 
Accessibility to PNA binding was a common feature of iso- 
lated hTR, as seven of the ten nontemplate-directed 
PNAs examined in these studies inhibited telomerase 
with IC50 values of less than 1 ~tM. Hybridized PNA 
either prevented holoenzyme formation or disrupted hTR 
structure within the holoenzyme, leading to less active 
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Figure 2 
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Telomere repeat amplification protocol (TRAP) gels showing inhibition 
of telomerase as a function of target sequence for PNA binding and 
holoenzyme structure. (a) The effect on telomerase activity of addition 
of PNAs 3, 4 and 7 to hTR prior to assembly of holoenzyme. Lane 1, no 
cell lysate added. Lane 2, no PNA added. Lane 3-7 PNA 3 at the 
following concentrations: 33 #M, 3.3 ixM, 330 nM, 33 nM and 3.3 nM. 
Lanes 8-12, PNA 4 added at the following concentrations: 33/.tM, 
3.3 IxM, 330 nM, 33 nM and 3.3 nM. Lanes 13-17 PNA 7 added at the 
following concentrations: 33 t.tM, 3.3 #M, 330 nM, 33 nM and 3.3 nM. 
(b) Effect on telomerase activity of addition of PNAs 3, 4 and 7 to 
reconstituted holoenzyme at the concentrations listed in (=a). 
enzyme in either case. Conversely, nontemplate-directed 
PNAs are almost entirely unable to inhibit the holoen- 
zyme, suggesting that binding of hTR to hTERT renders 
previously open target sequences inaccessible or stabilizes 
RNA structure sufficiently to prevent recognition by 
PNAs. The suggestion that the RNA structure is stabi- 
lized is supported by the observation that the half-life of 
hTR is much longer in cells that express hTERT relative 
to cells that do not [24]. 
PNA 8, which is targeted to bases 153-167, inhibited 
with a comparatively high IC50 value of 15 ~tM when 
added to hTR prior to holoenzyme assembly. Consistent 
with our observation Tesmer et al. (personal communica- 
tion), using genetic techniques, report the intriguing 
result that fragments panning +33 to +147 and +164 to 
+325 can be added together in trans to yield active telom- 
erase. This result suggests that the region between bases 
+147 and +164 does not contribute to catalysis. Tesmer et 
al. (personal communication) further suggested that the 
sequence between nucleotides +62 and +147 forms a 
nuclease-resistant hairpin structure in vitro. Our results 
support his suggestion. PNA 5, which is targeted within 
the putative hairpin stem, is a relatively poor inhibitor 
with an IC50 value of 1 ~M. PNAs 6 and 7, by contrast, 
are targeted to the predicted loop region, and possess 
tenfold more potent IC50 values of 100 nM. 
Surprisingly, we observe inhibition by PNAs targeted to 
regions of hTR that previous tudies have reported to be 
dispensable. For example, PNA 1, directed to bases 1-12, 
and PNA 12, directed to bases 430-442, both inhibit 
telomerase ven though these regions can be deleted 
without affecting activity. Such results demonstrate that 
RNA sequences that are unnecessary for catalysis may still 
be relevant argets for inhibitors designed to disrupt RNA 
structure. PNAs 10 (+180-194) and 11 (+291-303) had 
potent IC50 values of 10 and 50 nM, respectively. This 
result is consistent with reports that mutation or deletion 
of regions near the target sequences for 10 and 11 reduces 
telomerase activity ([13]; Tesmer et al. and W.E. Wright, 
personal communication) and suggests that these regions 
are not only functionally important but may form partially 
single-stranded structures that are highly accessible to 
PNA binding. 
Delivery of PNAs into cells by lipofection 
The results described above demonstrate that nontem- 
plate-directed PNAs are valuable reagents for probing 
RNA and holoenzyme structure within a cell-free system 
and reinforce the growing body of evidence that PNAs are 
likely to be widely useful probes for DNA and RNA struc- 
ture. Many of the most important questions that involve 
nucleic acid structure and function, however, can only be 
fully addressed in the context of the cell. To fully exploit 
the potential of PNAs as probes for structural biology and 
tools for chemical genetics it was therefore necessary for 
us to develop an efficient method for delivery of PNAs 
into eukaryotic ells. This issue is particularly pressing for 
telomerase because highly selective inhibitors are 
required to resolve the putative link between telomerase 
and cancer. 
Several methods have been developed for introducing 
PNAs into eukaryotic ells, including transient permeabi- 
lization with streptolysin O [25] and the conjugation of 
PNAs to peptides known to be internalized [26-28]. We 
describe here a new approach to PNA delivery that relies 
on well-established protocols for transfection using 
cationic lipid. For DNA and RNA the cationic lipid associ- 
ates with the negatively charged phosphodiester back- 
bone. The lipid-nucleic-acid complex can fuse with cell 
membranes, allowing oligonucleotide to enter cells 
through an endocytotic pathway, localize in the nucleus 
and regulate gene expression [29]. This approach was 
Figure 3 
(a) Transfection of PNA-DNA heteroduplexes to 
DU145 cells. (a) Scheme showing partially 
overlapping PNA-DNA heteroduplexes in 
complex with cationic lipid. (b) Fluorescence 
microscopy of cells upon after addition of 
rhodamine-labeled PNA 3-DNA-lipid 
complex. (c) Fluorescence microscopy of 
cells upon after addition of rhodamine-labeled 
PNA 3 and cationic lipid. (d) FACS analysis of 
cells transfected with PNA 3-DNA-lipid 
complex. The horizontal ine delineates 
fluorescence above background. The mean 
relative fluorescence for cells treated with 
DNA-PNA-rhodamine-lipid complex was 
3?.4. The mean relative fluorescence for cells 
alone and cells treated with DNA-PNA- 
rhodamine hybrid in the absence of lipid was 
4.1 and 6.7. 
(b) 
I 
DNA . . . . . .  
I 1 1 
PNA . . . . . .  
(c) (d) 
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attractive to us because cationic-lipid-mediated delivery of 
DNA and RNA is a simple and widely used method for 
introducing nucleic acids into cells [29] and because we 
had previously shown that lipofection could be used for 
intracellular delivery of 2'-O-meRNA inhibitors of telom- 
erase [30]. Lipofection does not require covalent chemical 
modification of the PNA, and if it could be employed for 
PNA delivery it would encourage immediate and wide- 
spread examination of the effects of PNAs within cells by 
researchers who are already familiar with lipid-mediated 
delivery of nucleic acids. 
To achieve lipid-mediated delivery of PNAs we hybridized 
PNAs to overlapping DNA oligonucleotides (Figure 3a), 
with the ll-15-base transporter DNA designed to have 
8-11 bases complementary to the cargo PNA. This 
complex was then mixed with cationic lipid and added to 
cells. The rationale for our approach is that the lipid should 
associate with the DNA strand, allowing the PNA strand to 
be imported as a passive cargo. Prior to our experiments it 
was not obvious that this approach would succeed because 
complexes between lipid and nucleic acids form an ordered 
structure [31] and it might have been expected that the 
attached PNA would disrupt lipid assembly. Once within 
the cell, the PNA should dissociate from the DNA and 
bind its target. The PNA-DNA hybrids were designed to 
overlap to promote nuclease degradation of the DNA com- 
ponent and dissociation of the hybrid. 
We first examined cellular uptake of PNAs using 
microscopy and fluorescence-activated c ll sorter (FACS) 
analysis. Microscopy of DU145 prostate-tumor-derived 
cells revealed that the uptake of rhodamine-labeled PNA 
in complex with complementary DNA and lipid was effi- 
cient and that PNA was distributed throughout the cell 
(Figure 3b). Similar results were also observed with Cos-7 
cells (data not shown). Uptake of rhodamine-labeled PNA 
alone, rhodamine-labeled PNA-lipid, or a rhodamine- 
labeled PNA-DNA hybrid in the absence of lipid was 
much less intense (Figure 3c). FACS analysis revealed 
that treatment with PNA-DNA-lipid complex resulted in 
delivery of rhodamine-labeled PNAs to greater than 90% 
of cells (Figure 3d). 
Inhibit ion of te lomerase  after l ip id -mediated del ivery of a 
template-d i rected PNA 
As an initial test of the ability of lipid-mediated transfec- 
tion to deliver PNA inhibitors of human telomerase we 
first examined inhibition by 13-base PNA 3 (Table 1) and 
l 1-base PNA 14 (GIy-CAGTTAGGGTT-Lys).  These 
two PNAs were chosen because they are directed to the 
intrinsically accessible ll-base template region of hTR 
and effective inhibitors of the holoenzyme (Table 1, 
Figure 2). Upon addition of complexes of DNA and lipid 
with either PNA 3 or PNA 14 to cultured DU145 cells we 
observed greater than 85% inhibition of telomerase activ- 
ity (Figure 4a). Inhibition is sequence specific, as transfec- 
tion of PNA 15 (N-GIy-AAGTTAGACAA-Lys) that 
contained mismatched bases did not result in inhibition of 
telomerase. Similar results were observed for inhibition of 
telomerase in 293 cells (an adenovirus-transformed human 
cell line). Inhibition was also specific to cells that had 
taken up PNA. When cells that were treated with the 
PNA-DNA-lipid complex were mixed with untreated 
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Inhibition of telomerase upon lipid-mediated 
transfection of template-directed PNAs. 
(a) Telomerase inhibition by PNAs directed to 
the template region of human telomerase. 
Transfection assays were performed for 6 h 
and included either no inhibitor, template- 
directed PNA 3, template-directed PNA 14 or 
a mismatch-containing PNA 15. (b) Inhibition 
of human telomerase by a template-directed 
PNA 3 as a function of incubation time of the 
PNA-DNA-lipid complex with cells. 
Telomerase activity was measured after 0, 
0.33, 2, 6 and 24 h. All transfection assays 
were performed in triplicate. 
cells we found that telomerase activity corresponded to 
that expected from the proportion of untreated cells. This 
result demonstrates that the highly efficient inhibition 
that we observe cannot be explained by PNA leaking from 
cells that have taken up PNA into cells that have not. 
The efficiency of inhibition by PNA 3 was dependent on 
the time allowed for incubation of the PNA-DNA-lipid 
complex with cells, and leveled at a maximum after 6 h 
(Figure 4b). Addition of DNA alone produced no inhibi- 
tion, nor did addition of the PNA-DNA complex in the 
absence of lipid or the PNA-lipid mixture in the absence 
of DNA. None of the PNA-DNA hybrids tested in these 
studies was toxic to cells upon transfection. This lack of 
toxicity may be due tothe reduced ability of PNAs to bind 
to proteins that normally bind to nucleic acids, and might 
be a general advantage for use of PNAs within cells. We 
continued to observe inhibition of telomerase activity for 
up to three days (or three population doublings) after trans- 
fection. This results suggests that PNAs persist in active 
form for days and that our DNA-PNA-lipid delivery 
method is adequate to deliver a dosage of PNA that 
remains effective after dilution due to repeated cell dou- 
blings. After a four-week treatment we observed telomere 
shortening, confirming that introduced PNAs are able to 
cause phenotypic hange in a sequence-specific manner 
(A. Pitts, •. Baker and D.R.C., unpublished observations). 
Inhibition of telomerase after lipid-mediated delivery of a 
nontemplate-directed PNA 
After establishing that lipid-mediated delivery of template- 
directed PNAs could inhibit cellular telomerase, we tested 
whether nontemplate-directed PNAs could also act as 
inhibitors inside cells. Inhibition by nontemplate-directed 
PNAs is a more severe test for the ability of PNAs to bind a 
biological target within cells because, unlike the accessible 
template region, binding to nontemplate sequences is 
likely to be hindered by nucleic-acid structure and 
protein-nucleic-acid interactions in the holoenzyme. 
We complexed PNAs 7 and 11 with partially complemen- 
tary DNA oligomers and lipid and transfected them into 
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Inhibition of telomerase upon transfection of nontemplate-directed PNAs. 
Telomerase activity was measured after (a) 6 h or (b) 24 h incubation 
time in the presence of PNA 15, 3, 7 or 11 complexed with DNA and 
lipid. Assays were performed in triplicate, and the quantitation is shown 
in (c). Residual activity was normalized to mismatched PNA 15. 
DU145 cells. We incubated cells with PNA-DNA-lipid 
complex for 6 h, the period that we had found to be ade- 
quate for maximal inhibition by template-directed PNA 3, 
and observed 53% inhibition by 7 and 40% inhibition by 
11. These levels of inhibition are significantly lower than 
those produced by template-directed PNAs 3 and 14 
(Figure 4). This result parallels our observations of inhibi- 
tion of reconstituted telomerase (Table 1), which show that 
the preformed telomerase holoenzyme present within cells 
is resistant o inhibition by nontemplate-directed PNAs. 
To increase the efficiency of inhibition we lengthened the 
time for incubation of the PNA-DNA-lipid complex with 
DU145 cells to 24 h. PNA 7 now inhibited 78% of telom- 
erase activity, whereas 11 inhibited 84%, indicating that 
the barrier to inhibition presented by holoenzyme struc- 
ture can be overcome within cells (Figure 5a-c). 
Inhibition of telomerase within cells suggests that lipid- 
meditated elivery of PNAs will facilitate antisense inhi- 
bition of gene expression by targeting mRNA. 
Intracellular PNA delivery will also allow testing of the 
hypothesis that PNAs have the potential to target genomic 
DNA by strand invasion. PNA binding within cells may 
also have significant applications beyond antisense inhibi- 
tion of gene expression. For example, fluorescently 
labeled oligonucleotides can be used as 'molecular 
beacons' for identifying mRNA in cells. This approach 
relies on the loss of fluorescence quenching of two fluo- 
rophores in a DNA hairpin upon binding a complementary 
sequence. We have already shown that PNA hairpins can 
bind to duplex DNA by strand invasion at 37°C, and it is 
reasonable to assume that they will also be able to bind 
RNA and that the insights we gain can be directly applied 
to this exciting technology. 
S ign i f i cance  
Elucidating the rules governing recognition of sequences 
within nucleic acid structure is fundamentally important 
for sequence-specific control of gene expression. We 
demonstrate hat recognition of sequ~ces within human 
telomerase by peptide nucleic a ids (PNAs) is stringently 
dependent on whether hTR (the RNA component of 
telomerase) is in complex with hTERT (the protein com- 
ponent) and on the precise location f the target site. 
Sequences are accessible when the RNA is in isolation, 
and most are inaccessible when present in the context of 
the holoenzyme. Accessibility of the RNA prior to 
holoenzyme formation offers an opportunity for inhibitor 
binding through interception of the uneomplexed RNA.  
As RNA and protein are synthesized separately within 
the cell, it is possible to envision this occurring in the 
intracellular milieu, enhancing the efficacy of nontem- 
plate-directed PNAs  and making them lead compounds 
for controlling telomere length and cell proliferation. 
This new class of telomerase inhibitors may prove par- 
ticularly valuable as components of combination 
inhibitor cocktails that overcome inhibitor esistance and 
curb the growth of proliferating cells in a clinical setting. 
Realizing the full potential of PNAs for control of any bio- 
logical process, including inhibition f human telomerase, 
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demands that methods be developed for the delivery of 
PNAs into cells. Ideally such methods hould be simple 
and general so that the advantages that PNAs have exhib- 
ited in cell-free systems [32] can be widely exploited by 
researchers. We demonstrate a convenient method for 
intracellular delivery, of PNAs using cationic lipids. 
Cationic-lipid-mediated delivery of nucleic acids is 
employed by many laboratories and our protocol should 
be readily adapted for wide use. IntraceUular delivery of 
PNAs is important because progress in genome sequenc- 
ing is revealing thousands of genes, many of which are 
closely related isoforms likely to play overlapping but not 
identical roles in cellular pathways. Convenient intracellu- 
l~r delivery will allow PNAs to join minor-groove-binding 
polyamides [33] and other chemical genetic strategies [34] 
for translating the one-dimensional understanding of 
protein function derived from genomic data into the multi- 
dimensional understanding necessary to understand cell 
signaling and regulation. 
Materials and methods 
Reconstitution of telomerase 
Constructs encoding the human telomerase protein component 
(XhTERT) and the RNA subunit (pTRC3) [12] were provided by 
J.W. Shay (University of Texas Southwestern Medical Center, Dallas 
TX). hTERT was synthesized in vitro using a rabbit reticulocyte tran- 
scription and translation system (Promega, Madison Wl). The RNA 
component was prepared using the MEGAscript TM T~ in vitro transcrip- 
tion system (Ambion, Austin TX). Reconstitution of hTR and hTERT to 
form telomerase holoenzyme was performed as described previously 
([15]; V.M. Tesmer, et aL, and W.E. Wright, personal communication). 
Telomerase assays, inhibition and PNA preparation 
Telomerase activity from immortal human prostate cancer cell line 
DU145 was detected using the TRAPeze kit (Intergen, Purchase NY) 
[24]. PNAs were added to hTR or the telomeraee holoenzyme. Solu- 
tions containing reconstituted telomerase and PNA were diluted from 
6 pl to a final volume of 50 p.I with CHAPS lysis buffer provided in the 
TRAPeze kit and 4 I.tl was used per amplification reaction. Cells trans- 
fected with oligonucleotides were lysed with CHAPS lysis buffer to a 
final concentration of 50 cells/I.d and 200 cell equivalents were used 
per assay reaction. PNAs were synthesized either using a PerSeptive 
Biosystem s (Framingham MA) Expedite 8909 Synthesizer and Fmoc 
chemistry [35], or manually using tBoc chemistry [36]. PNAs were puri- 
fied using reverse phase HPLC and analyzed using time-of-flight mass 
spectrometry (MALDI-TOF) as described previously [35]. 
Transfection of oligonucleotides and PNA-DNA 
heteroduplexes 
DU145 cells were plated at 25,000 cells/well on 24-well plates in Dul- 
becco's MEM containing 10% fetal calf serum and 500 U/ml penicillin 
and 0.1 mg/ml streptomycin and incubated at 3?°C at 5O/o CO 2 for 3 h. 
Oligomers (1 pM each) were pre-complexed with 2 p.I (7 I~g/ml) Lipo- 
fectAmine (Life Technologies, Gaithersburg MD) in a total of 200 #1 
Optimem (Life Technologies) for 45 min. The media was replaced with 
the lipofection-oligomer solution and the incubated 6-24 h. After incu- 
bation the transfection mixture was replaced with plating media and the 
incubation continued 12-15 h. Cells were washed once with 1 x PBS, 
treated with trypsin, harvested, counted and immediately assayed for 
telomerase inhibition as described above. DNA oligonucleotides and 
their partial PNA complements (in parentheses) were as follows 
5'-TCTAAC'ITI'AA-3' (PNA 15), 5'-TCTAACCCTAA-3' (PNA 3), 
5"-TCTCGCTGACT-3" (PNA 7), 5'-CCACTGCCACCGCG-3' (PNA 
11 ), and 5'-AATCCCAATCT-3' (PNA 14). 
Fluorescence microscopy and FA CS analysis 
PNA 3 was labeled with amino-terminal tetramethyl rhodamine (Mol- 
ecular Probes, Eugene OR) and cotransfected with DNA oligomer into 
DU145 cells as described above. Cells were rinsed four times with 
phosphate buffered saline (PBS) and fresh media was added. Cells 
were then incubated for 2 h and rinsed an additional four times with 
PBS. The intervening incubation was added to allow cells to withstand 
the extended washing necessary to ensure removal of free rhodamine 
from cell surfaces. Cells for evaluation using microscopy were rinsed 
once more with distilled water, transferred onto slides and mounted 
with GEL/MOUNT (Biomeda Corp., Foster City CA). Cells were visual- 
ized using an Olympus fluorescent microscope at 100 x magnification. 
Cells for FACS analysis were pelleted and resuspended in PBS and 
were sorted using a FACStarPlus flow cytometer (Becton Dickinson, 
Franklin Lakes N J). 
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